| Drug General Information |
| Drug ID |
D07JHG
|
| Former ID |
DNC003958
|
| Drug Name |
6-(3-Amino-benzyloxy)-9H-purin-2-ylamine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C12H12N6O
|
| Canonical SMILES |
C1=CC(=CC(=C1)N)COC2=NC(=NC3=C2NC=N3)N
|
| InChI |
1S/C12H12N6O/c13-8-3-1-2-7(4-8)5-19-11-9-10(16-6-15-9)17-12(14)18-11/h1-4,6H,5,13H2,(H3,14,15,16,17,18)
|
| InChIKey |
QCEFDVCKQLVMCW-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Cyclin-A2 |
Target Info |
Inhibitor |
[1]
|
|---|
| Cell division protein kinase 2 |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
DNA replication
|
|
Base excision repair
|
|
Nucleotide excision repair
|
|
Mismatch repair
|
|
Cell cycle
|
|
Hepatitis B
|
|
HTLV-I infectionhsa04068:FoxO signaling pathway
|
|
Oocyte meiosis
|
|
p53 signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Measles
|
|
Herpes simplex infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Viral carcinogenesis
|
|
Prostate cancer
|
|
Small cell lung cancer
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
p53 pathway
|
|
p53 pathway feedback loops 2
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Signaling events mediated by PRL
|
|
p73 transcription factor network
|
|
E2F transcription factor network
|
|
ATR signaling pathway
|
|
mTOR signaling pathway
|
|
IL2-mediated signaling events
|
|
FoxO family signaling
|
|
FOXM1 transcription factor network
|
|
BARD1 signaling events
|
|
p53 pathway
|
|
Regulation of retinoblastoma protein
|
|
PathWhiz Pathway
|
Nucleotide Excision Repair
|
|
Reactome
|
E2F mediated regulation of DNA replication
|
|
G0 and Early G1
|
|
Cdc20:Phospho-APC/C mediated degradation of Cyclin A
|
|
Regulation of APC/C activators between G1/S and early anaphase
|
|
SCF(Skp2)-mediated degradation of p27/p21
|
|
Senescence-Associated Secretory Phenotype (SASP)
|
|
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
|
|
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
|
|
HDR through Homologous Recombination (HRR)
|
|
Processing of DNA double-strand break ends
|
|
Dual Incision in GG-NER
|
|
Dual incision in TC-NER
|
|
Gap-filling DNA repair synthesis and ligation in TC-NER
|
|
G2 Phase
|
|
Orc1 removal from chromatin
|
|
G1/S-Specific Transcription
|
|
Cyclin A/B1 associated events during G2/M transition
|
|
Cyclin A:Cdk2-associated events at S phase entryR-HSA-1538133:G0 and Early G1
|
|
Activation of ATR in response to replication stress
|
|
DNA Damage/Telomere Stress Induced Senescence
|
|
Cyclin E associated events during G1/S transition
|
|
p53-Dependent G1 DNA Damage Response
|
|
Cyclin A:Cdk2-associated events at S phase entry
|
|
Meiotic recombination
|
|
Factors involved in megakaryocyte development and platelet production
|
|
WikiPathways
|
Senescence and Autophagy in Cancer
|
|
Mismatch repair
|
|
DNA Replication
|
|
G1 to S cell cycle control
|
|
EGF/EGFR Signaling Pathway
|
|
S Phase
|
|
Nifedipine Activity
|
|
Primary Focal Segmental Glomerulosclerosis FSGS
|
|
Retinoblastoma (RB) in Cancer
|
|
Integrated Pancreatic Cancer Pathway
|
|
Nucleotide Excision Repair
|
|
Telomere Maintenance
|
|
Synthesis of DNA
|
|
Mitotic G1-G1/S phases
|
|
Cell Cycle
|
|
Base Excision RepairWP707:DNA Damage Response
|
|
ID signaling pathway
|
|
M/G1 Transition
|
|
Meiotic Recombination
|
|
Aryl Hydrocarbon Receptor
|
|
ATM Signaling Pathway
|
|
Spinal Cord Injury
|
|
Oncostatin M Signaling Pathway
|
|
Prostate Cancer
|
|
Signaling Pathways in Glioblastoma
|
|
TSH signaling pathway
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Regulation of DNA replication
|
|
Mitotic G2-G2/M phases
|
|
Factors involved in megakaryocyte development and platelet production
|
|
APC/C-mediated degradation of cell cycle proteins
|
|
Cell Cycle Checkpoints
|
|
miRNA Regulation of DNA Damage Response
|
| References |
| REF 1 | J Med Chem. 2002 Aug 1;45(16):3381-93.Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. |
|---|
